Tag: Vaccine Technology
-
Eli Lilly Moves Into Trans-Amplifying RNA Vaccines With Amplitude Deal
Eli Lilly is expanding into next-generation RNA vaccines through a collaboration with Amplitude Therapeutics, gaining access to a trans-amplifying RNA platform designed to separate the replicase from the antigen payload and support multiple infectious-disease vaccine programs.
-
How Trans-Amplifying RNA Could Extend the mRNA Platform
Trans-amplifying RNA separates the replicase machinery from the antigen payload, creating a two-RNA amplification system. This BP Science explainer compares taRNA with conventional mRNA and self-amplifying RNA and examines why the split architecture could make amplified RNA vaccines more modular.
-
Moderna Wins FDA Approval for the First mRNA Flu Vaccine
FDA approval of Moderna’s mFlusiva marks the first U.S. approval of an mRNA flu vaccine and expands the platform beyond COVID-19.